Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Dirui Industrial Co.,Ltd. (300396.SZ)
Changchun, CN
Established in 1992, Dirui Industrial Co.,Ltd. focuses on the research, production, and marketing of diagnostic medical solutions, primarily within the People's Republic of China. The company's product portfolio encompasses a variety of medical apparatus, diagnostic reagents, and testing strips. They provide advanced analyzers for diverse applications, including biochemical blood cell analysis, urinalysis, coagulation studies, chemiluminescence immunoassay, and gynecological secretion examinations. Its corporate headquarters are located in Changchun, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.01% | +3.01% | -27.66% | -35.18% | -39.28% | -33.72% | -36.24% | -76.56% | -60.47% | -54.06% | -9.52% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%-33.7% Q1'26: -2.5% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%-273.1% Q1'26: -107.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-27.4% Q1'26: -12.4% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-32.9% Q1'26: +0.2% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%-18.0% Q1'26: +0.1% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%+0.1% Q1'26: -0.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×-2.57× Q1'26: 347.20× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
567.33M
est: 584.00M (-2.9%)
|
758.69M
est: 706.00M (+7.5%)
|
911.40M
est.
|
867.69M
est: 1.09B (-20.7%)
|
933.42M
est: 1.09B (-14.7%)
|
1.01B
est: 1.46B (-31.1%)
|
937.24M
est: 937.20M (+0.0%)
|
1.20B
est.
|
905.80M
est: 1.26B (-28.1%)
|
1.22B
est: 1.65B (-26.2%)
|
1.38B
est: 1.65B (-16.7%)
|
1.22B
est: 1.81B (-32.5%)
|
807.06M
est: 679.00M (+18.9%)
|
720.00M
720.00M – 720.00M
+6.0% YoY
|
801.00M
801.00M – 801.00M
+11.3% YoY
|
| EBITDA |
167.53M
est: 158.51M (+5.7%)
|
249.05M
est: 191.62M (+30.0%)
|
247.37M
est.
|
313.37M
est: 297.04M (+5.5%)
|
346.51M
est: 297.04M (+16.7%)
|
382.05M
est: 397.21M (-3.8%)
|
372.03M
est: 254.37M (+46.3%)
|
325.62M
est.
|
267.89M
est: 341.98M (-21.7%)
|
329.76M
est: 448.78M (-26.5%)
|
339.84M
est: 448.78M (-24.3%)
|
186.67M
est: 250.85M (-25.6%)
|
-218.76M
est: 94.36M (-331.8%)
|
100.06M
100.06M – 100.06M
+6.0% YoY
|
111.32M
111.32M – 111.32M
+11.3% YoY
|
| EBIT |
137.20M
est: 135.57M (+1.2%)
|
192.37M
est: 163.89M (+17.4%)
|
211.57M
est.
|
249.23M
est: 254.05M (-1.9%)
|
280.27M
est: 254.05M (+10.3%)
|
312.59M
est: 339.74M (-8.0%)
|
315.83M
est: 217.56M (+45.2%)
|
278.50M
est.
|
234.22M
est: 292.50M (-19.9%)
|
297.91M
est: 383.84M (-22.4%)
|
307.17M
est: 383.84M (-20.0%)
|
155.49M
est: 189.33M (-17.9%)
|
-265.44M
est: 71.22M (-472.7%)
|
75.52M
75.52M – 75.52M
+6.0% YoY
|
84.02M
84.02M – 84.02M
+11.2% YoY
|
| Net Income |
108.28M
est: 109.17M (-0.8%)
|
125.14M
est: 131.91M (-5.1%)
|
177.40M
est.
|
167.39M
est: 215.61M (-22.4%)
|
197.73M
est: 215.61M (-8.3%)
|
231.89M
est: 275.66M (-15.9%)
|
267.07M
est: 264.74M (+0.9%)
|
311.14M
est.
|
209.95M
est: 122.82M (+70.9%)
|
261.83M
est: 323.42M (-19.0%)
|
275.59M
est: 323.42M (-14.8%)
|
141.92M
est: 349.85M (-59.4%)
|
-245.99M
est: -27.33M (-800.0%)
|
51.93M
51.93M – 51.93M
+290.0% YoY
|
76.53M
76.53M – 76.53M
+47.4% YoY
|
| SGA |
217.23M
est: 77.45M (+180.5%)
|
303.61M
est: 93.63M (+224.3%)
|
120.87M
est.
|
239.90M
est: 145.14M (+65.3%)
|
234.66M
est: 145.14M (+61.7%)
|
236.23M
est: 194.09M (+21.7%)
|
192.49M
est: 124.29M (+54.9%)
|
159.11M
est.
|
185.38M
est: 167.10M (+10.9%)
|
251.40M
est: 219.29M (+14.6%)
|
304.52M
est: 219.29M (+38.9%)
|
283.27M
est: 354.78M (-20.2%)
|
95.60M
est: 133.46M (-28.4%)
|
141.52M
141.52M – 141.52M
+6.0% YoY
|
157.44M
157.44M – 157.44M
+11.3% YoY
|
| EPS |
0.39
est: 0.40 (-2.5%)
|
0.46
est: 0.48 (-4.8%)
|
0.65
est.
|
0.61
est: 0.79 (-22.8%)
|
0.72
est: 0.79 (-8.9%)
|
0.85
est: 1.01 (-15.8%)
|
0.97
est: 0.97 (+0.0%)
|
1.14
est.
|
0.76
est: 0.45 (+68.9%)
|
0.96
est: 1.19 (-19.0%)
|
1.01
est: 1.19 (-14.8%)
|
0.52
est: 1.28 (-59.4%)
|
-0.90
est: -0.10 (-800.0%)
|
0.19
0.19 – 0.19
+290.0% YoY
|
0.28
0.28 – 0.28
+47.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bo Wang | Deputy General Manager | — | male |
| Dandan Niu | Deputy General Manager | — | female |
| Guozhu An | Deputy GM, Board Secretary & Director | — | male |
| Haitao Zhang | Deputy General Manager | — | male |
| Mason Kim | Director of International Sales & Marketing | — | — |
| Shu Yan Lian | Accounting Supervisor | — | — |
| Xingyan Zhang | Deputy GM & Financial Director | — | female |
| Xuemin Wang | GM & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300396.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
